Pentraxin 3 Levels as a Marker of Chronic Inflammation in Patients With Metabolic Syndrome

Muhammed Kizilgul, Mehmet Uzunlulu, Melike Karacakaya, Aysun Semerci, Banu Isbilen, Ferruh K. Isman


Background: Pentraxin 3 (PTX3), an acute phase protein, is involved in chronic inflammation and does increase in atherosclerotic cardiovascular diseases. Metabolic syndrome (MetS) is characterized by chronic inflammation. We aimed to test the hypothesis of whether pentraxin 3 levels are high and do involve in chronic inflammation in patients with MetS. For that purpose, we investigated the association of PTX3 levels with chronic inflammation and its relation with metabolic parameters in patients with MetS compared to the patients with rheumatoid arthritis (RA) and healthy control cases.

Methods: We studied 22 non-diabetic adults ? 20 years of age. Patient population consisted of 27 cases with MetS diagnosed according to the IDF (International Diabetes Federation) definition (mean age 47.70 8.92). There were two control groups. The first group consisted of diseased control cases with rheumatoid arthritis (n = 28, mean age 45.93 13.18), and the second one consisted of healthy control cases (n = 27, mean age 46.18 9.27). Study groups were compared with demographic, anthropometric and biochemistry data, and serum PTX3 levels. Correlation analysis was used for determining the relation between PTX3 levels and cardiometabolic parameters. PTX3 levels were measured by ELISA method using Human Pentraxin-3/TSG-14 kit.

Results: Mean serum PTX3 levels were 0.73 0.53 ng/mL, 0.70 0.67 ng/mL and 0.78 0.65 ng/mL in the patients, diseased control, and healthy control groups, respectively. PTX3 levels were similar between the groups (P > 0.05). PTX3 levels and cardiometabolic parameters were not significantly correlated (P > 0.05).

Conclusion: These results do not confirm that PTX3 levels do increase as a marker of chronic inflammation in patients with MetS.

J Endocrinol Metab. 2012;2(6):220-227


Metabolic syndrome; Rheumatoid arthritis; Pentraxin 3

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.